secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001493152-23-016511
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix reports Q1 net loss $4.45M; cash runway extended to Q4 2024
---------------------------------------------------------------------

- Net loss of $4.45M ($1.22 per share) vs $4.97M loss in Q1 2022.
- Revenue $1.5M, up from $1.2M, mainly from Cipla agreement.
- Cash $30.8M; projected runway extended from Q2 2024 to Q4 2024.
- Phase 2b PUR1900 trial dosing initiated for ABPA; topline data expected mid-2024.
- Phase 1 PUR3100 migraine study positive; IND filing planned mid-2023, Phase 2 pending financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315223016511/0001493152-23-016511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315223016511/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer